Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Apr 23;286(6374):1309–1312. doi: 10.1136/bmj.286.6374.1309

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

J H Waxman, J A Wass, W F Hendry, H N Whitfield, G M Besser, J S Malpas, R T Oliver
PMCID: PMC1547625  PMID: 6404441

Abstract

Repeated administration of long acting analogues of gonadotrophin releasing hormone diminishes gonadal function and in men decreases testosterone concentrations; for this reason the effect of the analogue buserelin was studied in prostatic carcinoma. Twelve consecutive patients with newly diagnosed locally advanced or metastatic carcinoma of the prostate were treated. Each patient received intranasal buserelin in divided dosages of either 600 or 1000 micrograms daily. Suppression of the gonadotrophins and testosterone occurred in all patients. Objective and subjective signs of regression of disease were seen in nine patients. Buserelin offers an effective treatment of metastatic prostatic cancer without the side effects and cardiovascular risks associated with oestrogen treatment.

Full text

PDF
1309

Images in this article

1310FIG 1
on p.1310

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belchetz P. E., Plant T. M., Nakai Y., Keogh E. J., Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978 Nov 10;202(4368):631–633. doi: 10.1126/science.100883. [DOI] [PubMed] [Google Scholar]
  2. Bergquist C., Nillius S. J., Bergh T., Skarin G., Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh) 1979 Aug;91(4):601–608. doi: 10.1530/acta.0.0910601. [DOI] [PubMed] [Google Scholar]
  3. Bergquist C., Nillius S. J., Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception. 1979 May;19(5):497–506. doi: 10.1016/0010-7824(79)90064-7. [DOI] [PubMed] [Google Scholar]
  4. Blackard C. E., Byar D. P., Jordan W. P., Jr Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology. 1973 Jun;1(6):553–560. doi: 10.1016/0090-4295(73)90515-3. [DOI] [PubMed] [Google Scholar]
  5. Citrin D. L., Hogan T. F. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Cancer. 1982 Jul 15;50(2):201–206. doi: 10.1002/1097-0142(19820715)50:2<201::aid-cncr2820500205>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  6. Coy D. H., Schally A. V. Gonadotrophin releasing hormone analogues. Ann Clin Res. 1978;10(3):139–144. [PubMed] [Google Scholar]
  7. Fattah D. I., Chard T. Simplified method for measuring sex-hormone binding globulin. Clin Chem. 1981 Jul;27(7):1277–1279. [PubMed] [Google Scholar]
  8. Kastin A. J., Schally A. V., Gual C., Midgley A. R., Jr, Bowers C. Y., Diaz-Infante A., Jr Stimulation of LH release in men and women by LH-releasing hormone purified from porcine hypothalami. J Clin Endocrinol Metab. 1969 Aug;29(8):1046–1050. doi: 10.1210/jcem-29-8-1046. [DOI] [PubMed] [Google Scholar]
  9. Klijn J. G., de Jong F. H. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1982 May 29;1(8283):1213–1216. doi: 10.1016/s0140-6736(82)92339-x. [DOI] [PubMed] [Google Scholar]
  10. Laron Z., Kauli R., Zeev Z. B., Comaru-Schally A. M., Schally A. V. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet. 1981 Oct 31;2(8253):955–956. doi: 10.1016/s0140-6736(81)91155-7. [DOI] [PubMed] [Google Scholar]
  11. Lepor H., Ross A., Walsh P. C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol. 1982 Aug;128(2):335–340. doi: 10.1016/s0022-5347(17)52915-8. [DOI] [PubMed] [Google Scholar]
  12. Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
  13. Meldrum D. R., Chang R. J., Lu J., Vale W., Rivier J., Judd H. L. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab. 1982 May;54(5):1081–1083. doi: 10.1210/jcem-54-5-1081. [DOI] [PubMed] [Google Scholar]
  14. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  15. Tharandt L., Schulte H., Benker G., Hackenberg K., Reinwein D. Treatment of isolated gonadotropin deficiency in men with synthetic LR-RH and a more potent analogue of LH-RH. Neuroendocrinology. 1977;24(3-4):195–207. doi: 10.1159/000122708. [DOI] [PubMed] [Google Scholar]
  16. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wallace D. M., Chisholm G. D., Hendry W. F. T.N.M. classification for urological tumours (U.I.C.C.) - 1974. Br J Urol. 1975 Feb;47(1):1–12. doi: 10.1111/j.1464-410x.1975.tb03911.x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES